Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

News SummaryMost relevantAll newsSector news 

UK's NICE Backs Novartis Eye Drug, Reversing Earlier Guidance

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2012 | 01:16am CET

By Marta Falconi

ZURICH--The U.K.'s health costs watchdog has reversed earlier guidance and now recommends eye drug Lucentis for a new use, after its maker Novartis AG (>> Novartis AG) offered a better price.

The U.K's National Institute for Health and Clinical Excellence, or NICE, recommends the drug for certain patients who suffer from visual impairment caused by diabetic macular oedema, the regulator said Friday. Without discount, Lucentis costs 742.17 pounds ($1,195) per injection and is given monthly, NICE said.

The new draft guidance is now up for consultation.

NICE decides if particular treatments should be used on the state-run National Health Service. The watchdog had previously rejected Lucentis for diabetic macular oedema, a condition caused by fluid collecting in the central part of the retina, which leads to blurred central vision and other problems.

The drug is already recommended to treat wet age-related macular degeneration.

Novartis said it was pleased with NICE's decision, but lamented the watchdog's move to restrict Lucentis to only those patients with more thickened retinas.

"This has undervalued the benefits that Lucentis provides to all patients with visual impairment due to diabetic macular oedema," the company said.

The Swiss company said it will continue to work with NICE and other health authorities until final draft guidance is issued by early 2013.

Lucentis, which generated nearly 2.05 billion Swiss francs ($2.19 billion) in sales in 2011, was co-developed by Novartis and Swiss rival Roche Holding AG (ROG.VX). Novartis markets the medicine outside the U.S.

Write to Marta Falconi at marta.falconi@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Novartis AG
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS AG
12/09 NOVARTIS : Former Horsham Novartis site sold for 16m
12/09 NOVARTIS' : Ultibro Breezhaler improved lung function and COPD symptoms after di..
12/09 NOVARTIS : LEE011 (ribociclib) plus letrozole analyses show superior PFS across ..
12/09 NOVARTIS : Bitter Taster Gene
12/09 NOVARTIS : WLF Asks Court to Reject New Liability Theory that Would Drive Prescr..
12/08 NOVARTIS : Patent Issued for Silicone Hydrogel Lens with a Crosslinked Hydrophil..
12/08 NOVARTIS : Patent Issued for Wash Solution and Method for Affinity Chromatograph..
12/08 NOVARTIS : Patent Issued for Systems and Methods for an Electrocapillary Positiv..
12/08 NOVARTIS : David Epstein Joins as Special Advisor to Remedy Pharmaceuticals
12/08 NOVARTIS : Patent Issued for Systems and Processes for Inserting an Intraocular ..
More news
Sector news : Pharmaceuticals - NEC
12/09 FTSE records best week since July, Sky surges 27 percent on Fox bid
12/09DJASTRAZENECA : FDA Accepts License Application for Durvalumab
12/09DJBayer Teams Up With Versant to Develop Stem-Cell Therapies--Update
12/08 BRISTOL MYERS SQUIBB : Meyers Squibb to pay $19.5 million to settle off-label pr..
12/07 MYLAN : EpiPen maker Mylan to restructure, cut workforce
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/09 CANCER IMMUNOTHERAPY MARKET : 2016 Takeaways And What To Expect In 2017
12/09 Novartis' ribociclib plus letrozole significantly improves PFS in breast canc..
12/08 Don't Buy The Depomed Buyout Rumors; Buy The Certainty Of An Eventual Deal
12/07 GLOBAL BLOOD THERAPEUTICS : Short-Sellers Could Be In For A Ride
12/07 BeyondSpring Wants $100 Million IPO To Battle Cancer Immune Suppression
Financials ($)
Sales 2016 48 776 M
EBIT 2016 11 802 M
Net income 2016 8 046 M
Debt 2016 14 948 M
Yield 2016 4,07%
P/E ratio 2016 20,14
P/E ratio 2017 18,94
EV / Sales 2016 4,06x
EV / Sales 2017 3,98x
Capitalization 182 959 M
More Financials
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 83,4 $
Spread / Average Target 20%
Consensus details
EPS Revisions
More Estimates Revisions
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-18.49%182 959
JOHNSON & JOHNSON9.29%305 407
ROCHE HOLDING LTD.-17.58%193 824
PFIZER INC.-4.15%192 367
MERCK & CO., INC.15.92%168 820
SANOFI-2.89%104 027
More Results